
Cerenome Inc (CNSY) Stock Forecast & Price Target
Cerenome Inc (CNSY) Analyst Ratings
Bulls say
Cerenome is attractive fundamentally because it combines a differentiated CNS oncology pipeline with a commercial diagnostic platform, giving investors both clinical optionality and near-term revenue potential. REYOBIQ’s updated interim data showed clean safety with no DLTs in the multi-dose study, while CNSide generated first revenues of $722K from 222 tests, reached 26 institutions and 45 providers, and achieved payer coverage of about 190M lives. With LM and GBM toplines expected around mid-2027, CNSide projected to scale further, and cash plus debt support into 2028, the risk-reward profile appears compelling despite reimbursement and clinical execution risks.
Bears say
Cerenome is viewed negatively because its operating performance remains weak, with Q3 revenue of $722K only in line with consensus but a net loss of $1.14 per share versus the expected $0.98 loss, while Q2 2026 revenue of $0.4 million and EPS of $(1.31) both missed estimates materially. The company’s $4.9M cash balance at the end of Q3 may last into 1Q27, but reliance on ATM sales and the 3i facility underscores a significant financing overhang that can pressure the stock. Reflecting softer commercialization and ongoing losses, 2026 revenue estimates were cut to $3.0 million from $4.0 million and EPS to $(4.40) from $(3.77), signaling limited near-term fundamental improvement.
This aggregate rating is based on analysts' research of Cerenome Inc and is not a guaranteed prediction by Public.com or investment advice.
Cerenome Inc (CNSY) Analyst Forecast & Price Prediction
Start investing in Cerenome Inc (CNSY)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Cerenome Inc (CNSY) Forecast
Cerenome Inc (CNSY) Analyst Forecast & Price Prediction
Start investing in Cerenome Inc (CNSY)
Order type
Buy in
Order amount
Est. shares
0 shares